Event-Driven Stocks

OSIRIS THERAPEUTICS, INC.

Healthcare · Biological Products, (No Diagnostic Substances) · MD · SEC filings ↗ · Compare ⊕

Signs5 good2 warning2 severedetails ↓

Financials

SEC XBRL · annual
 FY18FY17FY16FY15FY14FY13
Revenue$142.8M$118.5M$10.1M$4.1M
Operating income$9.9M−$2.0M−$589,000−$9.0M$1.7M−$2.8M
Net income$36.9M$8.8M−$544,000−$8.7M
Total assets$101.5M$78.1M$72.6M$83.7M$98.1M$92.1M
Total liabilities$23.0M$36.7M$37.1M$15.8M$14.2M$11.1M
Equity$78.5M$41.4M$32.5M$67.9M$75.7M$80.9M
EPS (diluted)$1.07$0.25$-0.11$-1.04$-0.08
Shares out.34.5M34.5M34.5M34.4M34.2M32.9M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2018
Operating margin
6.9%
Net margin
25.8%
Return on equity
47.0%
Return on assets
36.4%
Return on capital (ROCE)
12.2%
Liabilities / assets
22.6%
Debt / equity
0.29×
Book value / share
$2.27
Revenue growth (YoY)
20.5%
Net income growth (YoY)
320.0%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2018
Altman Z″ (distress)
0.85distress
Accruals / assets
29.2%high accruals
Beneish M-Score
4.06elevated
Piotroski F-Score
7/9strong

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
68
/ 100
Profitability 100Growth 100Catalyst 33Earnings quality 33Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

2 severe2 warning5 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • High accruals — earnings-quality risk
  • Beneish M-Score elevated — earnings-manipulation screen flag
  • Operating margin is positive
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Positive operating cash flow

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.